메뉴 건너뛰기




Volumn 34, Issue 2, 2014, Pages 433-447

Treatment strategies in mastocytosis

Author keywords

Anti IgE; Antihistamine; Antimediator therapy; Mastocytosis; Mediator related symptoms; Platelet activating factor

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CLADRIBINE; CORTICOSTEROID; IMATINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTI-IGE ANTIBODIES; ANTIIDIOTYPIC ANTIBODY; DASATINIB; MONOCLONAL ANTIBODY; OMALIZUMAB; PLA2G7 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

EID: 84898783850     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.01.012     Document Type: Review
Times cited : (52)

References (109)
  • 1
    • 51649115383 scopus 로고    scopus 로고
    • Mast cells and mastocytosis
    • Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112(4):946-956.
    • (2008) Blood , vol.112 , Issue.4 , pp. 946-956
    • Metcalfe, D.D.1
  • 2
    • 34249333084 scopus 로고    scopus 로고
    • Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria
    • Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37(6):435-453.
    • (2007) Eur J Clin Invest , vol.37 , Issue.6 , pp. 435-453
    • Valent, P.1    Akin, C.2    Escribano, L.3
  • 3
    • 0034983045 scopus 로고    scopus 로고
    • Diagnostic criteria and classification of mastocytosis: a consensus proposal
    • Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25(7):603-625.
    • (2001) Leuk Res , vol.25 , Issue.7 , pp. 603-625
    • Valent, P.1    Horny, H.P.2    Escribano, L.3
  • 4
    • 84876926097 scopus 로고    scopus 로고
    • Prevalence of indolent systemic mastocytosis in a Dutch region
    • van Doormaal J.J., Arends S., Brunekreeft K.L., et al. Prevalence of indolent systemic mastocytosis in a Dutch region. JAllergy Clin Immunol 2013, 131(5):1429-1431.e1.
    • (2013) JAllergy Clin Immunol , vol.131 , Issue.5
    • van Doormaal, J.J.1    Arends, S.2    Brunekreeft, K.L.3
  • 5
    • 84884541237 scopus 로고    scopus 로고
    • Mastocytosis: update on pharmacotherapy and future directions
    • Cardet J.C., Akin C., Lee M.J. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013, 14(15):2033-2045.
    • (2013) Expert Opin Pharmacother , vol.14 , Issue.15 , pp. 2033-2045
    • Cardet, J.C.1    Akin, C.2    Lee, M.J.3
  • 7
    • 37749039528 scopus 로고    scopus 로고
    • Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
    • Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63(2):226-232.
    • (2008) Allergy , vol.63 , Issue.2 , pp. 226-232
    • Brockow, K.1    Jofer, C.2    Behrendt, H.3
  • 8
    • 84883214095 scopus 로고    scopus 로고
    • KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis
    • Broesby-Olsen S., Kristensen T., Vestergaard H., et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. JAllergy Clin Immunol 2013, 132(3):723-728.
    • (2013) JAllergy Clin Immunol , vol.132 , Issue.3 , pp. 723-728
    • Broesby-Olsen, S.1    Kristensen, T.2    Vestergaard, H.3
  • 9
    • 84895061744 scopus 로고    scopus 로고
    • Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    • Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. 2014;133(2):520-8.
    • (2014) , vol.133 , Issue.2 , pp. 520-528
    • Alvarez-Twose, I.1    Zanotti, R.2    Gonzalez-de-Olano, D.3
  • 10
    • 84885735607 scopus 로고    scopus 로고
    • Anaphylaxis caused by mosquito allergy in systemic mastocytosis
    • Reiter N., Reiter M., Altrichter S., et al. Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet 2013, 382(9901):1380.
    • (2013) Lancet , vol.382 , Issue.9901 , pp. 1380
    • Reiter, N.1    Reiter, M.2    Altrichter, S.3
  • 11
    • 67651120132 scopus 로고    scopus 로고
    • Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
    • Lim K.H., Tefferi A., Lasho T.L., et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113(23):5727-5736.
    • (2009) Blood , vol.113 , Issue.23 , pp. 5727-5736
    • Lim, K.H.1    Tefferi, A.2    Lasho, T.L.3
  • 12
    • 84890562829 scopus 로고    scopus 로고
    • Primary mast cell disorders in children
    • Fried A.J., Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013, 13(6):693-701.
    • (2013) Curr Allergy Asthma Rep , vol.13 , Issue.6 , pp. 693-701
    • Fried, A.J.1    Akin, C.2
  • 13
    • 84863115159 scopus 로고    scopus 로고
    • Childhood-onset mastocytosis
    • [in German]
    • Siebenhaar F., Weller K., Blume-Peytavi U., et al. Childhood-onset mastocytosis. Hautarzt 2012, 63(2):104-109. [in German].
    • (2012) Hautarzt , vol.63 , Issue.2 , pp. 104-109
    • Siebenhaar, F.1    Weller, K.2    Blume-Peytavi, U.3
  • 14
    • 0036202127 scopus 로고    scopus 로고
    • Cutaneous mastocytosis-clinical heterogeneity
    • Hartmann K., Henz B.M. Cutaneous mastocytosis-clinical heterogeneity. Int Arch Allergy Immunol 2002, 127(2):143-146.
    • (2002) Int Arch Allergy Immunol , vol.127 , Issue.2 , pp. 143-146
    • Hartmann, K.1    Henz, B.M.2
  • 15
    • 77953100303 scopus 로고    scopus 로고
    • Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus
    • Correia O., Duarte A.F., Quirino P., et al. Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus. Dermatol Online J 2010, 16(5):8.
    • (2010) Dermatol Online J , vol.16 , Issue.5 , pp. 8
    • Correia, O.1    Duarte, A.F.2    Quirino, P.3
  • 17
    • 84873095618 scopus 로고    scopus 로고
    • Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis
    • Bennett M., Chubar Y. Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis. Br J Haematol 2013, 160(4):420.
    • (2013) Br J Haematol , vol.160 , Issue.4 , pp. 420
    • Bennett, M.1    Chubar, Y.2
  • 18
    • 80051475544 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
    • Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011, 35(9):1143-1152.
    • (2011) Leuk Res , vol.35 , Issue.9 , pp. 1143-1152
    • Ustun, C.1    DeRemer, D.L.2    Akin, C.3
  • 19
    • 0141956431 scopus 로고    scopus 로고
    • Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells
    • Guhl S., Hartmann K., Tapkenhinrichs S., et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. JInvest Dermatol 2003, 121(4):837-844.
    • (2003) JInvest Dermatol , vol.121 , Issue.4 , pp. 837-844
    • Guhl, S.1    Hartmann, K.2    Tapkenhinrichs, S.3
  • 20
    • 0033890342 scopus 로고    scopus 로고
    • The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser
    • Bedlow A.J., Gharrie S., Harland C.C. The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser. JCutan Laser Ther 2000, 2(1):45-47.
    • (2000) JCutan Laser Ther , vol.2 , Issue.1 , pp. 45-47
    • Bedlow, A.J.1    Gharrie, S.2    Harland, C.C.3
  • 21
    • 55249087258 scopus 로고    scopus 로고
    • The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers
    • Resh B., Jones E., Glaser D.A. The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers. JCosmet Dermatol 2005, 4(2):78-82.
    • (2005) JCosmet Dermatol , vol.4 , Issue.2 , pp. 78-82
    • Resh, B.1    Jones, E.2    Glaser, D.A.3
  • 22
    • 84880260205 scopus 로고    scopus 로고
    • Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial
    • Siebenhaar F., Fortsch A., Krause K., et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013, 68(7):949-952.
    • (2013) Allergy , vol.68 , Issue.7 , pp. 949-952
    • Siebenhaar, F.1    Fortsch, A.2    Krause, K.3
  • 23
    • 61549112485 scopus 로고    scopus 로고
    • High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study
    • Siebenhaar F., Degener F., Zuberbier T., et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. JAllergy Clin Immunol 2009, 123(3):672-679.
    • (2009) JAllergy Clin Immunol , vol.123 , Issue.3 , pp. 672-679
    • Siebenhaar, F.1    Degener, F.2    Zuberbier, T.3
  • 24
    • 80052349904 scopus 로고    scopus 로고
    • H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects-a retrospective survey study
    • Weller K., Ziege C., Staubach P., et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects-a retrospective survey study. PloS One 2011, 6(9):e23931.
    • (2011) PloS One , vol.6 , Issue.9
    • Weller, K.1    Ziege, C.2    Staubach, P.3
  • 25
    • 70349210289 scopus 로고    scopus 로고
    • EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria
    • Zuberbier T., Asero R., Bindslev-Jensen C., et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64(10):1427-1443.
    • (2009) Allergy , vol.64 , Issue.10 , pp. 1427-1443
    • Zuberbier, T.1    Asero, R.2    Bindslev-Jensen, C.3
  • 26
    • 79960211070 scopus 로고    scopus 로고
    • Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant
    • Accessed June 29, 2011
    • Edwards A.M., Capkova S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep 2011, Accessed June 29, 2011. 10.1136/bcr.02.2011.3910.
    • (2011) BMJ Case Rep
    • Edwards, A.M.1    Capkova, S.2
  • 27
    • 76949102630 scopus 로고    scopus 로고
    • Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus
    • Vieira Dos Santos R., Magerl M., Martus P., et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010, 162(3):674-676.
    • (2010) Br J Dermatol , vol.162 , Issue.3 , pp. 674-676
    • Vieira Dos Santos, R.1    Magerl, M.2    Martus, P.3
  • 28
    • 0027217619 scopus 로고
    • Absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate
    • Yoshimi A., Hashizume H., Kitagawa M., et al. Absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate. Biol Pharm Bull 1993, 16(4):375-378.
    • (1993) Biol Pharm Bull , vol.16 , Issue.4 , pp. 375-378
    • Yoshimi, A.1    Hashizume, H.2    Kitagawa, M.3
  • 29
    • 0026511136 scopus 로고
    • Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine
    • Okayama Y., Benyon R.C., Rees P.H., et al. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992, 22(3):401-409.
    • (1992) Clin Exp Allergy , vol.22 , Issue.3 , pp. 401-409
    • Okayama, Y.1    Benyon, R.C.2    Rees, P.H.3
  • 30
    • 33747519112 scopus 로고    scopus 로고
    • Mast cell mediators in allergic inflammation and mastocytosis
    • Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006, 26(3):465-485.
    • (2006) Immunol Allergy Clin North Am , vol.26 , Issue.3 , pp. 465-485
    • Castells, M.1
  • 31
    • 0023877762 scopus 로고
    • Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063
    • Guinot P., Summerhayes C., Berdah L., et al. Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063. Lancet 1988, 2(8602):114.
    • (1988) Lancet , vol.2 , Issue.8602 , pp. 114
    • Guinot, P.1    Summerhayes, C.2    Berdah, L.3
  • 32
    • 0024343550 scopus 로고
    • Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis
    • Macpherson J.L., Kemp A., Rogers M., et al. Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 1989, 77(3):391-396.
    • (1989) Clin Exp Immunol , vol.77 , Issue.3 , pp. 391-396
    • Macpherson, J.L.1    Kemp, A.2    Rogers, M.3
  • 33
    • 84859109120 scopus 로고    scopus 로고
    • Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis
    • Turner P.J., Kemp A.S., Rogers M., et al. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012, 29(2):222-223.
    • (2012) Pediatr Dermatol , vol.29 , Issue.2 , pp. 222-223
    • Turner, P.J.1    Kemp, A.S.2    Rogers, M.3
  • 34
    • 0033946286 scopus 로고    scopus 로고
    • Gastrointestinal abnormalities and involvement in systemic mastocytosis
    • Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14(3):579-623.
    • (2000) Hematol Oncol Clin North Am , vol.14 , Issue.3 , pp. 579-623
    • Jensen, R.T.1
  • 35
    • 84884904326 scopus 로고    scopus 로고
    • Gastrointestinal manifestations in mastocytosis: a study of 83 patients
    • e1-3
    • Sokol H., Georgin-Lavialle S., Canioni D., et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. JAllergy Clin Immunol 2013, 132(4):866-873.e1-3.
    • (2013) JAllergy Clin Immunol , vol.132 , Issue.4 , pp. 866-873
    • Sokol, H.1    Georgin-Lavialle, S.2    Canioni, D.3
  • 36
    • 33646051264 scopus 로고    scopus 로고
    • Current options in the treatment of mast cell mediator-related symptoms in mastocytosis
    • Escribano L., Akin C., Castells M., et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006, 5(1):61-77.
    • (2006) Inflamm Allergy Drug Targets , vol.5 , Issue.1 , pp. 61-77
    • Escribano, L.1    Akin, C.2    Castells, M.3
  • 37
    • 0034992893 scopus 로고    scopus 로고
    • Mastocytosis: molecular mechanisms and clinical disease heterogeneity
    • Metcalfe D.D., Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001, 25(7):577-582.
    • (2001) Leuk Res , vol.25 , Issue.7 , pp. 577-582
    • Metcalfe, D.D.1    Akin, C.2
  • 38
    • 84862683302 scopus 로고    scopus 로고
    • Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression
    • Moura D.S., Sultan S., Georgin-Lavialle S., et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PloS One 2012, 7(6):e39468.
    • (2012) PloS One , vol.7 , Issue.6
    • Moura, D.S.1    Sultan, S.2    Georgin-Lavialle, S.3
  • 39
    • 80054848122 scopus 로고    scopus 로고
    • Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy
    • Moura D.S., Sultan S., Georgin-Lavialle S., et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PloS One 2011, 6(10):e26375.
    • (2011) PloS One , vol.6 , Issue.10
    • Moura, D.S.1    Sultan, S.2    Georgin-Lavialle, S.3
  • 40
    • 0022538802 scopus 로고
    • Mixed organic brain syndrome as a manifestation of systemic mastocytosis
    • Rogers M.P., Bloomingdale K., Murawski B.J., et al. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986, 48(6):437-447.
    • (1986) Psychosom Med , vol.48 , Issue.6 , pp. 437-447
    • Rogers, M.P.1    Bloomingdale, K.2    Murawski, B.J.3
  • 41
    • 0018687287 scopus 로고
    • Oral disodium cromoglycate in the treatment of systemic mastocytosis
    • Soter N.A., Austen K.F., Wasserman S.I. Oral disodium cromoglycate in the treatment of systemic mastocytosis. NEngl J Med 1979, 301(9):465-469.
    • (1979) NEngl J Med , vol.301 , Issue.9 , pp. 465-469
    • Soter, N.A.1    Austen, K.F.2    Wasserman, S.I.3
  • 42
    • 0025302361 scopus 로고
    • Cromolyn sodium in the management of systemic mastocytosis
    • Horan R.F., Sheffer A.L., Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. JAllergy Clin Immunol 1990, 85(5):852-855.
    • (1990) JAllergy Clin Immunol , vol.85 , Issue.5 , pp. 852-855
    • Horan, R.F.1    Sheffer, A.L.2    Austen, K.F.3
  • 43
    • 0024579966 scopus 로고
    • The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis
    • Mallet A.I., Norris P., Rendell N.B., et al. The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis. Br J Clin Pharmacol 1989, 27(1):88-91.
    • (1989) Br J Clin Pharmacol , vol.27 , Issue.1 , pp. 88-91
    • Mallet, A.I.1    Norris, P.2    Rendell, N.B.3
  • 44
    • 0028068094 scopus 로고
    • Radiotherapy of refractory bone pain due to systemic mast cell disease
    • Johnstone P.A., Mican J.M., Metcalfe D.D., et al. Radiotherapy of refractory bone pain due to systemic mast cell disease. Am J Clin Oncol 1994, 17(4):328-330.
    • (1994) Am J Clin Oncol , vol.17 , Issue.4 , pp. 328-330
    • Johnstone, P.A.1    Mican, J.M.2    Metcalfe, D.D.3
  • 45
    • 62849113861 scopus 로고    scopus 로고
    • Survey of aspirin administration in systemic mastocytosis
    • Butterfield J.H. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009, 88(3-4):122-124.
    • (2009) Prostaglandins Other Lipid Mediat , vol.88 , Issue.3-4 , pp. 122-124
    • Butterfield, J.H.1
  • 46
    • 0033945410 scopus 로고    scopus 로고
    • Treatment of systemic mast cell disorders
    • vii
    • Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14(3):659-687. vii.
    • (2000) Hematol Oncol Clin North Am , vol.14 , Issue.3 , pp. 659-687
    • Worobec, A.S.1
  • 47
    • 0036210051 scopus 로고    scopus 로고
    • Mastocytosis: current treatment concepts
    • Worobec A.S., Metcalfe D.D. Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 2002, 127(2):153-155.
    • (2002) Int Arch Allergy Immunol , vol.127 , Issue.2 , pp. 153-155
    • Worobec, A.S.1    Metcalfe, D.D.2
  • 48
    • 19544379538 scopus 로고    scopus 로고
    • Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment
    • Lim A.Y., Ostor A.J., Love S., et al. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005, 64(6):965-966.
    • (2005) Ann Rheum Dis , vol.64 , Issue.6 , pp. 965-966
    • Lim, A.Y.1    Ostor, A.J.2    Love, S.3
  • 49
    • 77953105527 scopus 로고    scopus 로고
    • Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient
    • Douglass J.A., Carroll K., Voskamp A., et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010, 65(7):926-927.
    • (2010) Allergy , vol.65 , Issue.7 , pp. 926-927
    • Douglass, J.A.1    Carroll, K.2    Voskamp, A.3
  • 50
    • 84885950853 scopus 로고    scopus 로고
    • Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis
    • Matito A., Blazquez-Goni C., Morgado J.M., et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 2013, 111(5):425-426.
    • (2013) Ann Allergy Asthma Immunol , vol.111 , Issue.5 , pp. 425-426
    • Matito, A.1    Blazquez-Goni, C.2    Morgado, J.M.3
  • 51
    • 34250826484 scopus 로고    scopus 로고
    • Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy
    • Siebenhaar F., Kuhn W., Zuberbier T., et al. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. JAllergy Clin Immunol 2007, 120(1):213-215.
    • (2007) JAllergy Clin Immunol , vol.120 , Issue.1 , pp. 213-215
    • Siebenhaar, F.1    Kuhn, W.2    Zuberbier, T.3
  • 52
    • 84874732930 scopus 로고    scopus 로고
    • Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria
    • Maurer M., Rosen K., Hsieh H.J., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. NEngl J Med 2013, 368(10):924-935.
    • (2013) NEngl J Med , vol.368 , Issue.10 , pp. 924-935
    • Maurer, M.1    Rosen, K.2    Hsieh, H.J.3
  • 53
    • 77955921599 scopus 로고    scopus 로고
    • Successful treatment of idiopathic anaphylaxis in an adolescent
    • [author reply: 6]
    • Pitt T.J., Cisneros N., Kalicinsky C., et al. Successful treatment of idiopathic anaphylaxis in an adolescent. JAllergy Clin Immunol 2010, 126(2):415-416. [author reply: 6].
    • (2010) JAllergy Clin Immunol , vol.126 , Issue.2 , pp. 415-416
    • Pitt, T.J.1    Cisneros, N.2    Kalicinsky, C.3
  • 54
    • 84871619423 scopus 로고    scopus 로고
    • Bone complications of mastocytosis: a link between clinical and biological characteristics
    • 75.e1-75.e7
    • Guillaume N., Desoutter J., Chandesris O., et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013, 126(1):75.e1-75.e7.
    • (2013) Am J Med , vol.126 , Issue.1
    • Guillaume, N.1    Desoutter, J.2    Chandesris, O.3
  • 55
    • 80052303003 scopus 로고    scopus 로고
    • Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis
    • Rossini M., Zanotti R., Bonadonna P., et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011, 49(4):880-885.
    • (2011) Bone , vol.49 , Issue.4 , pp. 880-885
    • Rossini, M.1    Zanotti, R.2    Bonadonna, P.3
  • 56
    • 84857191019 scopus 로고    scopus 로고
    • High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis
    • van der Veer E., van der Goot W., de Monchy J.G., et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012, 67(3):431-438.
    • (2012) Allergy , vol.67 , Issue.3 , pp. 431-438
    • van der Veer, E.1    van der Goot, W.2    de Monchy, J.G.3
  • 57
    • 84882879102 scopus 로고    scopus 로고
    • Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients
    • Hartmann K., Wagner N., Rabenhorst A., et al. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. JAllergy Clin Immunol 2013, 132(1):232-235.
    • (2013) JAllergy Clin Immunol , vol.132 , Issue.1 , pp. 232-235
    • Hartmann, K.1    Wagner, N.2    Rabenhorst, A.3
  • 58
    • 84887018065 scopus 로고    scopus 로고
    • Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis
    • Rabenhorst A., Christopeit B., Leja S., et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. JAllergy Clin Immunol 2013, 132(5):1234-1237.e7.
    • (2013) JAllergy Clin Immunol , vol.132 , Issue.5
    • Rabenhorst, A.1    Christopeit, B.2    Leja, S.3
  • 59
    • 33344458341 scopus 로고    scopus 로고
    • Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis
    • Kushnir-Sukhov N.M., Brittain E., Reynolds J.C., et al. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006, 139(3):265-270.
    • (2006) Int Arch Allergy Immunol , vol.139 , Issue.3 , pp. 265-270
    • Kushnir-Sukhov, N.M.1    Brittain, E.2    Reynolds, J.C.3
  • 60
    • 84893045853 scopus 로고    scopus 로고
    • Management of anaphylaxis: a systematic review
    • Dhami S., Panesar S.S., Roberts G., et al. Management of anaphylaxis: a systematic review. Allergy 2013, 69(2):168-175.
    • (2013) Allergy , vol.69 , Issue.2 , pp. 168-175
    • Dhami, S.1    Panesar, S.S.2    Roberts, G.3
  • 61
    • 31944443634 scopus 로고    scopus 로고
    • Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
    • Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. JAllergy Clin Immunol 2006, 117(2):391-397.
    • (2006) JAllergy Clin Immunol , vol.117 , Issue.2 , pp. 391-397
    • Sampson, H.A.1    Munoz-Furlong, A.2    Campbell, R.L.3
  • 62
    • 14744282580 scopus 로고    scopus 로고
    • Epidemiology of life-threatening and lethal anaphylaxis: a review
    • Moneret-Vautrin D.A., Morisset M., Flabbee J., et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005, 60(4):443-451.
    • (2005) Allergy , vol.60 , Issue.4 , pp. 443-451
    • Moneret-Vautrin, D.A.1    Morisset, M.2    Flabbee, J.3
  • 63
    • 1542616266 scopus 로고    scopus 로고
    • Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization
    • Bohlke K., Davis R.L., DeStefano F., et al. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. JAllergy Clin Immunol 2004, 113(3):536-542.
    • (2004) JAllergy Clin Immunol , vol.113 , Issue.3 , pp. 536-542
    • Bohlke, K.1    Davis, R.L.2    DeStefano, F.3
  • 64
    • 57149134229 scopus 로고    scopus 로고
    • The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project
    • Decker W.W., Campbell R.L., Manivannan V., et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. JAllergy Clin Immunol 2008, 122(6):1161-1165.
    • (2008) JAllergy Clin Immunol , vol.122 , Issue.6 , pp. 1161-1165
    • Decker, W.W.1    Campbell, R.L.2    Manivannan, V.3
  • 65
    • 1542286592 scopus 로고    scopus 로고
    • Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern
    • Helbling A., Hurni T., Mueller U.R., et al. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004, 34(2):285-290.
    • (2004) Clin Exp Allergy , vol.34 , Issue.2 , pp. 285-290
    • Helbling, A.1    Hurni, T.2    Mueller, U.R.3
  • 66
    • 0032827928 scopus 로고    scopus 로고
    • Epidemiology of anaphylaxis in Olmsted County: a population-based study
    • Yocum M.W., Butterfield J.H., Klein J.S., et al. Epidemiology of anaphylaxis in Olmsted County: a population-based study. JAllergy Clin Immunol 1999, 104(2 Pt 1):452-456.
    • (1999) JAllergy Clin Immunol , vol.104 , Issue.2 PART 1 , pp. 452-456
    • Yocum, M.W.1    Butterfield, J.H.2    Klein, J.S.3
  • 67
    • 33845217089 scopus 로고    scopus 로고
    • Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group
    • Lieberman P., Camargo C.A., Bohlke K., et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006, 97(5):596-602.
    • (2006) Ann Allergy Asthma Immunol , vol.97 , Issue.5 , pp. 596-602
    • Lieberman, P.1    Camargo, C.A.2    Bohlke, K.3
  • 68
    • 20144389124 scopus 로고    scopus 로고
    • Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes
    • Florian S., Krauth M.T., Simonitsch-Klupp I., et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005, 136(3):273-280.
    • (2005) Int Arch Allergy Immunol , vol.136 , Issue.3 , pp. 273-280
    • Florian, S.1    Krauth, M.T.2    Simonitsch-Klupp, I.3
  • 69
    • 34648816795 scopus 로고    scopus 로고
    • Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)
    • Gonzalez de Olano D., de la Hoz Caballer B., Nunez Lopez R., et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007, 37(10):1547-1555.
    • (2007) Clin Exp Allergy , vol.37 , Issue.10 , pp. 1547-1555
    • Gonzalez de Olano, D.1    de la Hoz Caballer, B.2    Nunez Lopez, R.3
  • 70
    • 84890813890 scopus 로고    scopus 로고
    • High prevalence of anaphylaxis in patients with systemic mastocytosis-a single-center experience
    • Gulen T., Hagglund H., Dahlen B., et al. High prevalence of anaphylaxis in patients with systemic mastocytosis-a single-center experience. Clin Exp Allergy 2013, 44(1):121-129.
    • (2013) Clin Exp Allergy , vol.44 , Issue.1 , pp. 121-129
    • Gulen, T.1    Hagglund, H.2    Dahlen, B.3
  • 71
    • 77954340281 scopus 로고    scopus 로고
    • IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis
    • Matito A., Bartolome-Zavala B., Alvarez-Twose I., et al. IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis. Allergy 2010, 65(8):1058-1059.
    • (2010) Allergy , vol.65 , Issue.8 , pp. 1058-1059
    • Matito, A.1    Bartolome-Zavala, B.2    Alvarez-Twose, I.3
  • 72
    • 84882868503 scopus 로고    scopus 로고
    • Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis
    • van Anrooij B., van der Veer E., de Monchy J.G., et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. JAllergy Clin Immunol 2013, 132(1):125-130.
    • (2013) JAllergy Clin Immunol , vol.132 , Issue.1 , pp. 125-130
    • van Anrooij, B.1    van der Veer, E.2    de Monchy, J.G.3
  • 73
    • 84873404919 scopus 로고    scopus 로고
    • Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis
    • Alvarez-Twose I., Bonadonna P., Matito A., et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. JAllergy Clin Immunol 2013, 131(2):614-615.
    • (2013) JAllergy Clin Immunol , vol.131 , Issue.2 , pp. 614-615
    • Alvarez-Twose, I.1    Bonadonna, P.2    Matito, A.3
  • 74
    • 0033393227 scopus 로고    scopus 로고
    • Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels
    • Biedermann T., Rueff F., Sander C.A., et al. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol 1999, 141(6):1110-1112.
    • (1999) Br J Dermatol , vol.141 , Issue.6 , pp. 1110-1112
    • Biedermann, T.1    Rueff, F.2    Sander, C.A.3
  • 75
    • 77949355609 scopus 로고    scopus 로고
    • Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy
    • Dugas-Breit S., Przybilla B., Dugas M., et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010, 40(4):643-649.
    • (2010) Clin Exp Allergy , vol.40 , Issue.4 , pp. 643-649
    • Dugas-Breit, S.1    Przybilla, B.2    Dugas, M.3
  • 76
    • 84903362676 scopus 로고    scopus 로고
    • Insect stings: clinical features and management
    • Przybilla B., Rueff F. Insect stings: clinical features and management. Dtsch Arztebl Int 2012, 109(13):238-248.
    • (2012) Dtsch Arztebl Int , vol.109 , Issue.13 , pp. 238-248
    • Przybilla, B.1    Rueff, F.2
  • 78
    • 34249787870 scopus 로고    scopus 로고
    • Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
    • Carter M.C., Robyn J.A., Bressler P.B., et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. JAllergy Clin Immunol 2007, 119(6):1550-1551.
    • (2007) JAllergy Clin Immunol , vol.119 , Issue.6 , pp. 1550-1551
    • Carter, M.C.1    Robyn, J.A.2    Bressler, P.B.3
  • 79
    • 38949092068 scopus 로고    scopus 로고
    • High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis
    • Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008, 63(3):376-378.
    • (2008) Allergy , vol.63 , Issue.3 , pp. 376-378
    • Kontou-Fili, K.1
  • 80
    • 68949208094 scopus 로고    scopus 로고
    • Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis
    • Kontou-Fili K., Filis C.I. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009, 64(9):1384-1385.
    • (2009) Allergy , vol.64 , Issue.9 , pp. 1384-1385
    • Kontou-Fili, K.1    Filis, C.I.2
  • 81
    • 77953149438 scopus 로고    scopus 로고
    • Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE
    • Kontou-Fili K., Filis C.I., Voulgari C., et al. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 2010, 104(6):537-539.
    • (2010) Ann Allergy Asthma Immunol , vol.104 , Issue.6 , pp. 537-539
    • Kontou-Fili, K.1    Filis, C.I.2    Voulgari, C.3
  • 82
    • 0033800085 scopus 로고    scopus 로고
    • C-Kit and c-kit mutations in mastocytosis and other hematological diseases
    • Boissan M., Feger F., Guillosson J.J., et al. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. JLeukoc Biol 2000, 67(2):135-148.
    • (2000) JLeukoc Biol , vol.67 , Issue.2 , pp. 135-148
    • Boissan, M.1    Feger, F.2    Guillosson, J.J.3
  • 83
    • 84887658376 scopus 로고    scopus 로고
    • Comprehensive mutational profiling in advanced systemic mastocytosis
    • Schwaab J., Schnittger S., Sotlar K., et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013, 122(14):2460-2466.
    • (2013) Blood , vol.122 , Issue.14 , pp. 2460-2466
    • Schwaab, J.1    Schnittger, S.2    Sotlar, K.3
  • 84
    • 84870766228 scopus 로고    scopus 로고
    • In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells
    • Soucie E., Hanssens K., Mercher T., et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012, 120(24):4846-4849.
    • (2012) Blood , vol.120 , Issue.24 , pp. 4846-4849
    • Soucie, E.1    Hanssens, K.2    Mercher, T.3
  • 85
    • 67349145955 scopus 로고    scopus 로고
    • Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
    • Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23(5):900-904.
    • (2009) Leukemia , vol.23 , Issue.5 , pp. 900-904
    • Tefferi, A.1    Levine, R.L.2    Lim, K.H.3
  • 86
    • 84865062086 scopus 로고    scopus 로고
    • Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis
    • Traina F., Visconte V., Jankowska A.M., et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PloS One 2012, 7(8):e43090.
    • (2012) PloS One , vol.7 , Issue.8
    • Traina, F.1    Visconte, V.2    Jankowska, A.M.3
  • 87
    • 84862252300 scopus 로고    scopus 로고
    • Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis
    • Alvarez-Twose I., Gonzalez P., Morgado J.M., et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. JClin Oncol 2012, 30(12):e126-e129.
    • (2012) JClin Oncol , vol.30 , Issue.12
    • Alvarez-Twose, I.1    Gonzalez, P.2    Morgado, J.M.3
  • 88
    • 84872800619 scopus 로고    scopus 로고
    • KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial
    • Gotlib J., Kluin-Nelemans H.C., George T.I., et al. KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial. Blood 2012, 120:799.
    • (2012) Blood , vol.120 , pp. 799
    • Gotlib, J.1    Kluin-Nelemans, H.C.2    George, T.I.3
  • 89
    • 78649504351 scopus 로고    scopus 로고
    • Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study
    • Paul C., Sans B., Suarez F., et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85(12):921-925.
    • (2010) Am J Hematol , vol.85 , Issue.12 , pp. 921-925
    • Paul, C.1    Sans, B.2    Suarez, F.3
  • 90
    • 70449707323 scopus 로고    scopus 로고
    • Are we ready to downregulate mast cells?
    • Karra L., Berent-Maoz B., Ben-Zimra M., et al. Are we ready to downregulate mast cells?. Curr Opin Immunol 2009, 21(6):708-714.
    • (2009) Curr Opin Immunol , vol.21 , Issue.6 , pp. 708-714
    • Karra, L.1    Berent-Maoz, B.2    Ben-Zimra, M.3
  • 91
    • 79960915632 scopus 로고    scopus 로고
    • Down-regulation of mast cell responses through ITIM containing inhibitory receptors
    • Karra L., Levi-Schaffer F. Down-regulation of mast cell responses through ITIM containing inhibitory receptors. Adv Exp Med Biol 2011, 716:143-159.
    • (2011) Adv Exp Med Biol , vol.716 , pp. 143-159
    • Karra, L.1    Levi-Schaffer, F.2
  • 93
    • 77950862195 scopus 로고    scopus 로고
    • Human mast cells express intracellular TRAIL
    • Berent-Maoz B., Salemi S., Mankuta D., et al. Human mast cells express intracellular TRAIL. Cell Immunol 2010, 262(2):80-83.
    • (2010) Cell Immunol , vol.262 , Issue.2 , pp. 80-83
    • Berent-Maoz, B.1    Salemi, S.2    Mankuta, D.3
  • 94
    • 73949158887 scopus 로고    scopus 로고
    • Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs
    • Aichberger K.J., Gleixner K.V., Mirkina I., et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009, 114(26):5342-5351.
    • (2009) Blood , vol.114 , Issue.26 , pp. 5342-5351
    • Aichberger, K.J.1    Gleixner, K.V.2    Mirkina, I.3
  • 95
    • 13544251714 scopus 로고    scopus 로고
    • Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation
    • Alfredsson J., Puthalakath H., Martin H., et al. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ 2005, 12(2):136-144.
    • (2005) Cell Death Differ , vol.12 , Issue.2 , pp. 136-144
    • Alfredsson, J.1    Puthalakath, H.2    Martin, H.3
  • 96
    • 36048986227 scopus 로고    scopus 로고
    • The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells
    • Ekoff M., Kaufmann T., Engstrom M., et al. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 2007, 110(9):3209-3217.
    • (2007) Blood , vol.110 , Issue.9 , pp. 3209-3217
    • Ekoff, M.1    Kaufmann, T.2    Engstrom, M.3
  • 97
    • 0042926577 scopus 로고    scopus 로고
    • Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis
    • Hartmann K., Artuc M., Baldus S.E., et al. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am J Pathol 2003, 163(3):819-826.
    • (2003) Am J Pathol , vol.163 , Issue.3 , pp. 819-826
    • Hartmann, K.1    Artuc, M.2    Baldus, S.E.3
  • 98
    • 77956914323 scopus 로고    scopus 로고
    • The BH3-mimetic ABT-737 induces mast cell apoptosis invitro and invivo: potential for therapeutics
    • Karlberg M., Ekoff M., Huang D.C., et al. The BH3-mimetic ABT-737 induces mast cell apoptosis invitro and invivo: potential for therapeutics. JImmunol 2010, 185(4):2555-2562.
    • (2010) JImmunol , vol.185 , Issue.4 , pp. 2555-2562
    • Karlberg, M.1    Ekoff, M.2    Huang, D.C.3
  • 99
    • 84897019340 scopus 로고    scopus 로고
    • The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells
    • Peter B., Cerny-Reiterer S., Hadzijusufovic E., et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. JLeukoc Biol 2013, 95(1):95-104.
    • (2013) JLeukoc Biol , vol.95 , Issue.1 , pp. 95-104
    • Peter, B.1    Cerny-Reiterer, S.2    Hadzijusufovic, E.3
  • 100
    • 84886788913 scopus 로고    scopus 로고
    • Dimethylfumarate induces apoptosis in human mast cells
    • Forster A., Preussner L.M., Seeger J.M., et al. Dimethylfumarate induces apoptosis in human mast cells. Exp Dermatol 2013, 22(11):719-724.
    • (2013) Exp Dermatol , vol.22 , Issue.11 , pp. 719-724
    • Forster, A.1    Preussner, L.M.2    Seeger, J.M.3
  • 101
    • 83455238362 scopus 로고    scopus 로고
    • Mast cells as targets of pimecrolimus
    • Ma Z., Jiao Z. Mast cells as targets of pimecrolimus. Curr Pharm Des 2011, 17(34):3823-3829.
    • (2011) Curr Pharm Des , vol.17 , Issue.34 , pp. 3823-3829
    • Ma, Z.1    Jiao, Z.2
  • 102
    • 77953605142 scopus 로고    scopus 로고
    • Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis
    • Ma Z., Tovar J.P., Kwong K.Y., et al. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol 2010, 153(4):413-418.
    • (2010) Int Arch Allergy Immunol , vol.153 , Issue.4 , pp. 413-418
    • Ma, Z.1    Tovar, J.P.2    Kwong, K.Y.3
  • 103
    • 84874113715 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria
    • Magerl M., Rother M., Bieber T., et al. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. JEur Acad Dermatol Venereol 2012, 27(3):e363-e369.
    • (2012) JEur Acad Dermatol Venereol , vol.27 , Issue.3
    • Magerl, M.1    Rother, M.2    Bieber, T.3
  • 104
    • 84880221843 scopus 로고    scopus 로고
    • Miltefosine: a novel treatment option for mast cell-mediated diseases
    • Maurer M., Magerl M., Metz M., et al. Miltefosine: a novel treatment option for mast cell-mediated diseases. JDermatolog Treat 2013, 24(4):244-249.
    • (2013) JDermatolog Treat , vol.24 , Issue.4 , pp. 244-249
    • Maurer, M.1    Magerl, M.2    Metz, M.3
  • 105
    • 58549114489 scopus 로고    scopus 로고
    • Miltefosine inhibits human mast cell activation and mediator release both invitro and invivo
    • Weller K., Artuc M., Jennings G., et al. Miltefosine inhibits human mast cell activation and mediator release both invitro and invivo. JInvest Dermatol 2009, 129(2):496-498.
    • (2009) JInvest Dermatol , vol.129 , Issue.2 , pp. 496-498
    • Weller, K.1    Artuc, M.2    Jennings, G.3
  • 106
    • 72749127841 scopus 로고    scopus 로고
    • Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial
    • Hartmann K., Siebenhaar F., Belloni B., et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2010, 162(1):185-190.
    • (2010) Br J Dermatol , vol.162 , Issue.1 , pp. 185-190
    • Hartmann, K.1    Siebenhaar, F.2    Belloni, B.3
  • 107
    • 79951495806 scopus 로고    scopus 로고
    • Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit
    • Gerbaulet A., Wickenhauser C., Scholten J., et al. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 2011, 117(6):2012-2021.
    • (2011) Blood , vol.117 , Issue.6 , pp. 2012-2021
    • Gerbaulet, A.1    Wickenhauser, C.2    Scholten, J.3
  • 108
    • 41649098497 scopus 로고    scopus 로고
    • Mast cell functions in the innate skin immune system
    • Metz M., Siebenhaar F., Maurer M. Mast cell functions in the innate skin immune system. Immunobiology 2008, 213(3-4):251-260.
    • (2008) Immunobiology , vol.213 , Issue.3-4 , pp. 251-260
    • Metz, M.1    Siebenhaar, F.2    Maurer, M.3
  • 109
    • 41549096026 scopus 로고    scopus 로고
    • Mast cell-driven skin inflammation is impaired in the absence of sensory nerves
    • Siebenhaar F., Magerl M., Peters E.M., et al. Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. JAllergy Clin Immunol 2008, 121(4):955-961.
    • (2008) JAllergy Clin Immunol , vol.121 , Issue.4 , pp. 955-961
    • Siebenhaar, F.1    Magerl, M.2    Peters, E.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.